Kura Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Net Income	-152.63	-135.84	-130.47	-89.63	-63.14	-60.45	-35.43	-27.56	-22.63
Depreciation & Amortization	0.85	0.76	0.56	0.19	0	0.01	0.03	0.03	0.02
Share-Based Compensation	28.08	26.32	23.58	12.81	9.41	8.65	4.55	2.09	2.26
Other Operating Activities	-1.12	-1.3	1.78	6.79	-1.03	3.13	2.42	0.09	2.42
Operating Cash Flow	-124.82	-110.06	-104.55	-69.83	-54.76	-48.66	-28.44	-25.35	-17.93
Capital Expenditures	-0.17	-0.63	-1.15	-2.17	0	0	0	0	-0.06
Change in Investments	15.73	33.25	-125.69	-97.77	-46.33	-79.3	-23.42	12.18	-70.56
Investing Cash Flow	15.56	32.63	-126.84	-99.94	-46.33	-79.3	-23.42	12.18	-70.63
Share Issuance / Repurchase	94.78	29.14	4.43	469.58	111.1	133.26	53.91	0	97.87
Debt Issued / Paid	0	9.43	-7.86	-0.25	0	-0.62	-0.34	7.45	5
Financing Cash Flow	94.78	38.57	-3.44	469.33	111.1	132.64	53.57	7.45	102.87
Net Cash Flow	-14.48	-38.87	-234.82	299.57	10.02	4.69	1.71	-5.72	14.32
Free Cash Flow	-124.99	-110.69	-105.7	-72	-54.76	-48.66	-28.44	-25.35	-17.99
Free Cash Flow Per Share	-1.71	-1.65	-1.59	-1.36	-1.30	-1.38	-1.22	-1.35	-1.81

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).